endpoint was demonstration of pharmacokinetic equivalence of ABP 501 relative to adalimumab, based on area under the serum concentration-time curve (AUC) from time 0 extrapolated to infinity (AUC inf ) and the maximum observed serum concentration (C max ). Pre-specified equivalence criterion for all parameters was 90% confidence interval (CI) for geometric means (GM ) ratio within 0.80 to 1.25. Secondary endpoints included the safety, tolerability, and immunogenicity.
R e su l ts: A total of 67 subjects received ABP 501 and 67 subjects received adalimumab (EU). Following single dose, the GM of C max , AUC last and AUC inf for ABP 501 were 3.22ng/ml, 2002.27 ng.h/ml and 2136.95ng.h/ml and a median t max of 190.82 hr. The GM of C max , AUC last and AUC inf for adalimumab (EU) were 3.37 ng/ml, 2022.62 ng.h/ml and 2046.82 ng.h/ml and a median t max of 168.00 hr. Ratio of adjusted least square geometric means (90% CIs) between ABP 501 and adalimumab (EU) for C max was 0.96 (0.89, 1.03); AUC inf was 1.04 (0.93, 1.17) and AUC last was 0.99 (0.89, 1.10). The 90% CIs of GM ratio for C max , AUC inf , and AUC last were fully contained within 0.80 to 1.25, confirming the bioequivalence between ABP 501 and adalimumab (EU).
There were no treatment related serious adverse events, or treatment related adverse events leading to discontinuation from the study. The most frequently reported treatment-related AEs included headache, nausea, nasopharyngitis, and oropharyngeal pain.
No pre-existing anti-drug antibodies (ADA) were detected at baseline. In the ABP 501 treatment group, 36 (54%) subjects developed binding antibodies and 12 (18%) developed neutralizing antibodies. In the adalimumab (EU) treatment group, 45 (67%) subjects developed binding antibodies and 14 (21%) developed neutralizing antibodies. 
